Core Viewpoint - Think Surgical is accelerating its global market expansion and product development in the orthopedic surgical robot sector, particularly through the appointment of Chris Marrus as EVP to lead the TMINI surgical robot business and the 2026 growth plan [1][2]. Strategic Plan and Growth Objectives - Chris Marrus's addition signifies a pivotal step for Think Surgical in enhancing its global market reach and product innovation [2]. - The growth plan aims to increase the installation of TMINI surgical robots from 500 units to 1,500 units by the end of 2026, focusing on the U.S., Europe, and Asia-Pacific markets [2]. New Indication Development - The plan includes expanding TMINI's applications from knee replacement to hip and shoulder surgeries, with FDA approval expected in 2026 [3]. Technology Upgrades - Think Surgical is set to develop an AI-driven surgical planning algorithm, with TMINI 2.0 scheduled for launch in 2026, integrating real-time feedback during surgeries [4]. Financing Goals - The company plans to initiate a funding round of $200-300 million by the end of 2025 to support global expansion and R&D efforts [5]. About Chris Marrus - Chris Marrus brings over 20 years of experience in the medical technology industry, particularly in surgical robotics, having held significant roles at Intuitive Surgical and Mako Surgical [7]. - His previous achievements include driving over 20% annual sales growth for the da Vinci surgical system and leading the promotion of Mako Rio, which was later acquired by Stryker for $1.6 billion [7]. About THINK Surgical - Founded in 2007, THINK Surgical is based in the U.S. and specializes in developing and manufacturing robotic systems for knee replacement surgeries [10]. - The TMINI system, launched around 2022, is the world's first miniaturized surgical robot, featuring a wireless handheld device that assists surgeons with precise bone cutting during knee surgeries [10].